MaxCyte (MXCT) has released an update.
MaxCyte Inc., a leader in cell-engineering platform technologies, has announced a change of its Nominated Adviser and Joint Broker’s name to Panmure Liberum Limited following the merger of Panmure Gordon (UK) Limited and Liberum Capital Limited. This update reflects the company’s continued progress in the cell therapy sector, leveraging its ExPERT platform to support the development and commercialization of advanced cell-based therapies.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
